Moderna is preparing for multiple product launches over the next several years, including RSV and flu vaccines and boosters for COVID-19. It is also aiming mRNA programs at rare diseases.
https://www.pharmalive.com/wp-content/uploads/2021/08/Moderna-Bolsters-mRNA-Oncology-Business-with-Autolus-Proprietary-Binders-BioSpace-8-2-21.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-09-09 10:44:322022-09-09 12:09:08With 34 vaccine programs in development, Moderna eyes global launches
